The Center for Disease Control (CDC) has issued its Considerations for Distinguishing Influenza-Like Illness from Inhalational Anthrax.

CDC has issued guidelines on the evaluation of persons with a history of exposure to Bacillus anthracis spores or who have an occupational or environmental risk for anthrax exposure (1). This notice describes the clinical evaluation of persons who are not known to be at increased risk for anthrax but who have symptoms of influenza-like illness (ILI). Clinicians evaluating persons with ILI should consider a combination of epidemiologic, clinical, and, if indicated, laboratory and radiographic test results to evaluate the likelihood that inhalational anthrax is the basis for ILI symptoms.

Some other good links are provided at the end of the report:

Additional information about anthrax is available at
<http://www.hhs.gov/hottopics/healing/biological.html> and
< ttp://www.bt.cdc.gov/DocumentsApp/FactsAbout/FactsAbout.asp>. Additional information about influenza, RSV and other
viral respiratory infections, and pneumococcal disease is available at
<http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm>, <http://www.cdc.gov/nip/flu/default.htm>,
<http://www.cdc.gov/ncidod/dvrd/revb/index.htm>,
<http://www.cdc.gov/ncidod/dbmd/diseaseinfo/streppneum_t.htm>, and <http://www.cdc.gov/nip/diseases/Pneumo/vac-chart.htm>.